Cyclo-oxygenase (COX) inhibitors for treating preterm labour

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 6, 2015, Pages

  Reinebrant, Hanna E ^a   Pileggi Castro, Cynthia ^b   Romero, Carla L T ^b   dos Santos, Rafaela A N ^b   Kumar, Sailesh ^c   Souza, João Paulo ^b   Flenady, Vicki ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c MATER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; MAGNESIUM SULFATE; OXYTOCIN ANTAGONIST; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; UTERUS SPASMOLYTIC AGENT;

BIRTH; BIRTH WEIGHT; CLINICAL OUTCOME; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GESTATIONAL AGE; HUMAN; MATERNAL DEATH; MEDICAL DECISION MAKING; META ANALYSIS; NEWBORN MORBIDITY; NEWBORN MORTALITY; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; FEMALE; PREGNANCY; PREMATURE BIRTH; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CALCIUM CHANNEL BLOCKERS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INDOMETHACIN; MAGNESIUM SULFATE; PREGNANCY; PREMATURE BIRTH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOCOLYTIC AGENTS;

EID: 84945164831     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001992.pub3     Document Type: Review

References (111)

1. Asgharnia M, Sobhani A, Omidvar-Jalali Z. Comparison of Mg-Sulfate and indomethacin in management of women with preterm labor. Journal of Gorgan University of Medical Sciences 2002;4(2):7-12.
2. Besinger RE, Niebyl JR, Keyes WG, Johnson TR. Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor. American Journal of Obstetrics and Gynecology 1991;164(4):981-8.
3. Borna S, Saeidi FM. Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research 2007;33(5):631-4.
4. Kashanian M, Bahasadri S, Zolali B. Comparison of the efficacy and adverse effects of nifedipine and indomethacin for the treatment of preterm labor. International Journal of Gynecology & Obstetrics 2011;113(3):192-5.
5. Klauser CK, Briery CM, Keiser SD, Martin RW, Kosek MA, Morrison JC. Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal-Fetal and Neonatal Medicine 2012;25(12):2778-81.
6. Klauser CK, Briery CM, Martin RW, Langston L, Magann EF, Morrison JC. A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal-Fetal & Neonatal Medicine 2014;27(8):801-6.
7. Kramer W, Saade G, Belfort M, Dorman K, Mayes MMK. Randomized double-blind study comparing sulindac to terbutaline: fetal cardiovascular effects. American Journal of Obstetrics and Gynecology 1996;174(1 Pt 2):326.
8. Kramer WB, Saade GR, Belfort M, Dorman K, Mayes M, Moise KJ. A randomized double-blind study comparing the fetal effects of sulindac to terbutaline during the management of preterm labor. American Journal of Obstetrics and Gynecology 1999;180(2):396-401.
9. Eronen M. The hemodynamic effects of antenatal indomethacin in a beta-sympathomimetic agent on the fetus and the newborn: a randomized study. Pediatric Research 1993;33(6):615-9.
10. Eronen M, Pesonen E, Kurki T, Ylikorkala O, Hallman M. The effects of indomethacin and beta-sympathomimetic agent on the fetal ductus arteriosus during treatment of premature labor: A randomized double-blind study. American Journal of Obstetrics and Gynecology 1991;164:141-6.
11. Eronen N, Pesonen E, Kurki T, Teramo K, Ylikorkala O, Hallman M. Increased incidence of bronchopulmonary dysplasia after antenatal administration of indomethacin to prevent preterm labor. Journal of Pediatrics 1994;124:782-8.
12. Kurki T, Eronen M, Lumme R, Ylikorkala O. A randomized double-dummy comparison between indomethacin and nylidrin in threatened preterm labor. Obstetrics & Gynecology 1991;78(6):1093-7.
13. Kurki T, Laatikainen T, Salminen-Lappalainen K, Ylikorkala O. Maternal plasma corticotrophin-releasing hormone - elevated in preterm labour but unaffected by indomethacin or nylidrin. British Journal of Obstetrics and Gynaecology 1991;98:685-91.
14. Kurki T, Schultz E, Linden IB, Ylikorkala O. Catechol-O-methyltransferase activity in red blood cells in threatened preterm labor: effect of indomethacin and nylidrin. Acta Obstetricia et Gynecologica Scandinavica 1991;70:187-91.
15. Lumme R, Kurki T, Pyorala T, Ylikorkala O. Indomethacin is more effective than nylidrine in arresting preterm labor. Proceedings of 2nd European Congress on Prostaglandins in Reproduction; 1991 April 30-May 3; The Hague, Netherlands. 1991:202.
16. Salokorpi T, Eronen M, von Wendt L. Growth and development until 18 months of children exposed to tocolytics indomethacin or nylidrin. Neuropediatrics 1996;27:147-7.
17. McWhorter J, Carlan S, O'Leary T, Richici K, O'Brien W. Rofecoxib versus magnesium sulfate to arrest preterm labour: a randomised trial. Obstetrics & Gynecology 2004;103:923-30.
18. McWhorter J, Carlan SJ, O'Leary TD. Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double-blind trial. Obstetrics & Gynecology 2002;99(4 Suppl 1):2S.
19. Morales WJ, Smith SG, Angel JL, O'Brien WF. Efficacy and safety of indomethacin vs ritodrine in the management of preterm labor: a randomized study. Proceedings of 9th Annual Meeting of the Society of Perinatal Obstetricians; 1989 Feb 1-4; New Orleans, Louisiana, USA. 1989:35.
20. Morales WJ, Smith SG, Angel JL, O'Brien WF, Knuppel RA. Efficacy and safety of indomethacin versus ritodrine in the management of preterm labor: a randomized study. Obstetrics & Gynecology 1989;74(4):567-72.
21. Morales WJ, Madhav H. Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. JAMA 1993;270:2676.
22. Morales WJ, Madhav H. Efficacy and safety of indomethacin compared with magnesium sulfate in the management or preterm labor: a randomized study. American Journal of Obstetrics and Gynecology 1993;169(1):97-102.
23. Morales WJ, Madhav H. Efficacy and safety of indomethacin vs. magnesium in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology 1991;164:280.
24. Nevils B, Curet L, Izquierdo L, Chatterjee M, Gilson G, Maciulla J, et al. Indomethacin as a "rescue" tocolytic in pre-term labor. American Journal of Obstetrics and Gynecology 1994;170:378.
25. Blake DA, Niebyl JR, White RD, Kumor KM, Dubin NH, Robinson JC, et al. Treatment of premature labor with indomethacin. Advances in prostaglandin, thromboxane and leukotriene research 1980;8:1465-7.
26. Niebyl JR, Blake DA, White RD, Kumor KM, Dubin NH, Robinson JC, et al. The inhibition of premature labor with indomethacin. American Journal of Obstetrics and Gynecology 1980;136(8):1014-9.
27. Odeh M, Kaiis M, Markowitz J, Oettinger M. Progesterone levels in preterm labor are not affected by ritodrin treatment. Gynecologic and Obstetric Investigation 1997;43(1):34-6.
28. Cavalle-Garrido T, Panter K, Smallhorn J, Seaward D, Farine D. A RCT of indomethacin for preterm labor: effects on fetal heart and ductus arteriosus. American Journal of Obstetrics and Gynecology 1997;176(1 Pt 2):S46.
29. Panter K, Hannah M, Farine D, Amankwah K, Jefferies A, Ohlsson A. The effect of indomethacin tocolysis of preterm labor on perinatal outcome: a RCT. American Journal of Obstetrics and Gynecology 1997;176(1 Pt 2):S46.
30. Panter KR, Hannah ME, Amankwah KS, Ohlsson A, Jefferies AL, Farine D. The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomised placebo-controlled trial. British Journal of Obstetrics and Gynaecology 1999;106(5):467-73.
31. Parilla BV, Tamura RK, Cohen LS, Clark E. Lack of effect of antenatal indomethacin on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology 1997;176(6):1166-71.
32. Purwaka BT, Abadi A, Prasetyadi FOH. Comparison of efficacy between oral nimesulide and parenteral-oral isoxsuprine to delay threatened preterm labour. Journal of Obstetrics and Gynaecology Research 2004;30(3):264.
33. Sawdy RJ, Lye S, Fisk NM, Bennett PR. A double-blind randomized study of fetal side effects during and after the short-term maternal administration of indomethacin, sulindac, and nimesulide for the treatment of preterm labor. American Journal of Obstetrics and Gynecology 2003;188:1046-51.
34. Schorr SJ, Ascarelli MH, Rust OA, Ross EL, Calfee EL, Perry KG Jr, et al. A comparative study of ketorolac (Toradol) and magnesium sulfate for arrest of preterm labor. Southern Medical Journal 1998;91(11):1028-32.
35. Schorr SJ, Ascarelli MH, Rust OA, Ross EL, Calfee EL, Perry KG Jr, et al. Ketorolac is a safe and effective drug for acute tocolysis. American Journal of Obstetrics and Gynecology 1997;176(1):S7.
36. Stika CS, Gross GA, Leguizamon G, Gerber S, Levy R, Mathur A, et al. A prospective randomized safety trial of celecoxib for treatment of preterm labor. American Journal of Obstetrics and Gynecology 2002;187(3):653-60.
37. Zuckerman H, Shalev E, Gilad G, Katzuni E. Further study of the inhibition of premature labor by indomethacin. Part II double-blind study. Journal of Perinatal Medicine 1984;12(1):25-9.
38. Abramov Y, Nadjari M, Weinstein D, Ben-Shachar I, Plotkin V, Ezra Y. Indomethacin for preterm labor: a randomized comparision of vaginal and rectal-oral routes. Obstetrics & Gynecology 2000;95(4):482-6.
39. Bartfield M, Carlan SJ. The safety and efficacy of prolonged outpatient sulindac to prevent the recurrence of preterm labor: a prospective double-blind study. Primary Care Update for Ob/Gyns 1998;5(4):178.
40. Bivins HA, Newman RB, Fyfe DA, Campbell BA, Stramm SL. Randomized comparative trial of indomethacin and terbutaline for the long term treatment of preterm labor. American Journal of Obstetrics and Gynecology 1993;168(1 Pt 2):375.
41. Bivins HA, Newman RB, Fyfe DA, Campbell BA, Stramm SL. Randomized trial of oral indomethacin and terbutaline sulfate for the long-term suppression of preterm labor. American Journal of Obstetrics and Gynecology 1993;169:1065-70.
42. Caballero A, Tejerina A, Dominguez A, Nava JM, Caballero AJ. Indomethacine alone or associated to ritodrine in the prevention of premature labour [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 Oct 26-31;Tokyo, Japan. 1979:300.
43. Carlan SJ, O'Brien WF, O'Leary TD, Mastrogiannis D. Randomized comparative trial of indomethacin and sulindac for the treatment of refactory preterm labor. Obstetrics & Gynecology 1992;79(2):223-8.
44. Carlan SJ, O'Brien WF, O'Leary TD, Mastrogiannis DS. A randomized comparative trial of indomethacin and sulindac for the treatment of refactory preterm labor. American Journal of Obstetrics and Gynecology 1992;166:361.
45. Carlan S, Jones M, Schorr S, McNeill T, Rawji H, Clark K. Oral sulindac to prevent recurrence of preterm labor. American Journal of Obstetrics and Gynecology 1994;170:381.
46. Carlan SJ, O'Brien WF, Jones MH, O'Leary TD, Roth L. Outpatient oral sulindac to prevent recurrence of preterm labor. Obstetrics & Gynecology 1995;85:769-74.
47. Jones M, Carlan S, Schorr S, McNeill T, Rawji H, Clark K, et al. Oral sulindac to prevent recurrence of preterm labor. American Journal of Obstetrics and Gynecology 1995;172:416.
48. Ehsanipoor RM, Shrivastava VK, Lee RM, Chan K, Galyean AM, Garite TJ, et al. A randomized, double-masked trial of prophylactic indomethacin tocolysis versus placebo in women with premature rupture of membranes. American Journal of Perinatology 2011;28(6):473-8.
49. Shrivastava V, Ehsanipoor R, Lee RM, Chan K, Gaylean A, Garite T, et al. Randomized double-blinded trial of indomethacin tocolysis versus expectant management in patients with premature rupture of membranes at 24-32 weeks of gestation. American Journal of Obstetrics and Gynecology 2008;199(6 Suppl 1):S59.
50. Gamissans O, Canas E, Cararach V, Ribas J, Puerto B, Edo A. A study of indomethacin combined with ritodrine in threatened preterm labor. European Journal of Obstetrics & Gynecology and Reproductive Biology 1978;8:123-8.
51. Gamissans O, Canas E, Cararach V, Ribas J, Puerto B, Edo A. A study of indomethacin combined with ritodrine in threatened preterm labor. Proceedings of 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1 Vienna, Austria. 1978:Abstract no: 165.
52. Gamissans O, Cararach V, Serra J. The role of prostaglandin-inhibitors, beta-adrenergic drugs and glucocorticoids in the management of threatened preterm labor. In: Jung H, Lamberti G editor(s). Beta-Mimetic Drugs in Obstetrics and Perinatology. Stuttgart: Georg Thieme, 1982:71-84.
53. Gamissans O, Balasch J. Prostaglandin synthetase inhibitors in the treatment of preterm labor. In: Fuchs F, Stubblefield PG editor(s). Preterm Birth: Causes, Prevention and Management. New York: Macmillan, 1984:223-48.
54. Groom KM, Shennan AH, Jones BA, Seed P, Bennett PR. Tocox--a randomised, double-blind, placebo-controlled trial of rofecoxib (a cox-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk. BJOG: an international journal of obstetrics and gynaecology 2005;112:725-30.
55. Hallak M, Moise KJ, Lira N, Dorman K, O'Brian Smith E, Cotton DB. The effect of tocolytic agents (indomethacin and terbutaline) on fetal breathing (FBM) and body movements (FM): a prospective, randomized, double blind, placebo-controlled clinical trial. American Journal of Obstetrics and Gynecology 1992;166(1 Pt 2):375.
56. Hallak M, Moise KJ, Lira N, Dorman KF, O'Brian Smith E, Cotton DB. The effect of tocolytic agents (indomethacin and terbutaline) on fetal breathing and body movements: a prospective, randomized, double-blind, placebo-controlled clinical trial. American Journal of Obstetrics and Gynecology 1992;167(4):1059-63.
57. Hallak M, Moise KJ, O'Brian Smith E, Cotton DB. The effects of indomethacin and terbutaline on human fetal umbilical artery velocimetry: a randomized double-blind study. American Journal of Obstetrics and Gynecology 1993;168(1 Pt 2):348.
58. Hallak M, Moise KJ, O'Brian Smith E, Cotton DB. The effects of indomethacin and terbutaline on human fetal umbilical artery velocimetry: a randomized, double-blind study. American Journal of Obstetrics and Gynecology 1993;168(3):865-8.
59. Humphrey RG, Bartfield MC, Carlan SJ, O'Brien WF, O'Leary TD, Triana T. Sulindac to prevent recurrent preterm labor: a randomized controlled trial. Obstetrics & Gynecology 2001;98(4):555-62.
60. Jain N, Gahlot D. A comparative study of isoxuprine versus ritodrine hydrochloride in the management of preterm labour [abstract]. 49th All India Congress of Obstetrics and Gynaecology; 2006 January 6-9; Cochin, Kerala State, India. 2006:148.
61. Katz Z, Lancet M, Yemini M, Mogilner BM, Feigl A, Ben-Hur H. Treatment of premature labor contractions with combined ritodrine and indomethacine. International Journal of Gynecology & Obstetrics 1983;21:337-42.
62. Khuteta RP, Garg S, Bhargava A. Mefanimic acid in prevention of premature labour. 12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil. 1988:222.
63. Mital P, Garg S, Khuteta RP, Khuteta S, Mital P. Mefenamic acid in prevention of premature labour. Journal of the Royal Society of Health 1992;112(5):214-6.
64. Newton ER, Shields L, Ridgway LE, Berkus MD, Elliott BD. Combination antibiotics and indomethacin in idiopathic preterm labor: a randomized double-blind clinical trial. American Journal of Obstetrics and Gynecology 1991;165(6):1753-9.
65. Ridgway L, Wright J, Newton E. The effect of indomethacin on fetal heart biometry. American Journal of Obstetrics and Gynecology 1991;164:349.
66. Jouppila P, Rasanen J. Response of the fetal hemodynamics to different maternal prostaglandin synthetase inhibitors. Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland. 1994:Abstract no: 269.
67. Jouppila P, Rasanen J. Response to the fetal hemodynamics to different maternal prostaglandin synthetase inhibitors. International Journal of Gynecology & Obstetrics 1994;46:48.
68. Rasanen J, Jouppila P. Fetal cardiac function and ductus arteriosus during indomethacin and sulindac therapy for threatened preterm labor: a randomized study. American Journal of Obstetrics and Gynecology 1995;173(1):20-5.
69. Rios-Anez R, Santos-Luque M, Noguera M. Use of an antagonist of the prostaglandins associated to a b-sympathomimetic agent in the treatment of pre-term labour. Journal of Perinatal Medicine 2001;29 Suppl 1(Pt 1):165.
70. Spearing G. Alcohol, indomethacin and salbutamol. A comparative trial of their use in preterm labour. Obstetrics & Gynecology 1979;53:171-4.
71. Zuckerman H, Shalev E, Gilad G, Katzuni E. Further study of the inhibition of premature labor by indomethacin Part I. Journal of Perinatal Medicine 1984;12:19-23.
72. Castillo JM, Alonso J, Hernandez-Garcia JM, Sancho B, Martinez V. Study of biochemical and biophysical modifications produced on pregnant women treated in threatened of premature labor with ritodrine and indometacine. 12th World Congress of Gynecology and Obstetrics; 1988 Oct 23-28; Rio de Janeiro, Brazil. 1988:20.
73. Mesdaghinia E, Mesdaghinia A, Hashemi T, Sooky Z, Mousavi GA. Comparing the effects fo indomethacin and magnesium-sufate in the treatment of preterm labor. Feyz, Journal of Kashan University of Medical Sciences 2012;16(2):95-101.
74. Sooky Z. Comparison of delaying in premature labour by indomethacin and Mg sulphate in pregnant women referred to maternity hospital. IRCT Iranian Registry of Clinical Trials (www.irct.ir) (accessed 6 December 2010) 2010.
75. Babay Z, Lange IR, Amin H. Neonatal and maternal complications after administration of indomethacin for preterm labour between 24 and 30 weeks gestation. Journal of the Society of Obstetricians and Gynaecologists of Canada 1998;20(5):505-11.
76. Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD001060]
77. Doret M, Mellier G, Benchaib M, Piacenza JM, Gharib C, Pasquier JC. In vitro study of tocolytic effect of rofecoxib, a specific cyclo-oxygenase 2 inhibitor. Comparison and combination with other tocolytic agents. BJOG: an international journal of obstetrics and gynaecology 2002;109:983-8.
78. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3]
79. Duckitt K, Thornton S, O'Donovan OP, Dowswell T. Nitric oxide donors for treating preterm labour. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD002860.pub2]
80. Eronen M, Pesonen E, Kurki T, Teramo K, Ylikorkola O, Hallman M. Increased incidence of bronchopulmonary dysplasia after antenatal administration of indomethacin to prevent preterm labor. Journal of Pediatrics 1994;124(5):783-8.
81. U.S. Food, Drug Administration. Drug Safety Communication: New warnings against use of terbutaline to treat preterm labor. http://www.fda.gov/Drugs/DrugSafety/ucm243539.htm.
82. Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD004452.pub3]
83. Flenady V, Wojcieszek AM, Papatsonis DNM, Stock OM, Murray L, Jardine LA, et al. Calcium channel blockers for inhibiting preterm labour and birth. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD002255.pub2]
84. Gates S, Brocklehurst P. How should randomised trials including multiple pregnancies be analysed?. BJOG: an international journal of obstetrics and gynaecology 2004;111(3):213-9.
85. Gladstone M, Neilson JP, White S, Kafulafula G, van den Broek N. Post-neonatal mortality, morbidity, and developmental outcome after ultrasound-dated preterm birth in rural Malawi: a community-based cohort study. PLoS Medicine 2011;8:e1001121.
86. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008;371:75-84.
87. Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ 2012;345:e6226.
88. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
89. Keirse MJNC. Inhibitors of prostaglandin synthesis for treatment of preterm labour. In: Drife JO, Calder AA editor(s). Prostaglandins and the Uterus. London: Springer-Verlag, 1992.
90. Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Annals of Pharmacotherapy 2006;40(5):824-9.
91. McCain GC, Deatrick JA. The experience of high-risk pregnancy. Journal of Obstetric, Gynecologic and Neonatal Nursing 1993;23:421-7.
92. Moise KJ, Ou C-N, Kirshon B, Cano LE, Carpenter RJ. Placental transfer of indomethacin in the human pregnancy. American Journal of Obstetrics and Gynecology 1990;162:549-54.
93. Murray M. Antepartal and Intrapartal Fetal Monitoring. Springer Publishing Company, 2006.
94. Neilson JP, West HM, Dowswell T. Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3]
95. Norman JE, Morris C, Chalmers J. The effect of changing patterns of obstetric care in Scotland (1980-2004) on rates of preterm birth and its neonatal consequences: perinatal database study. PLoS Medicine 2009;6(9):e1000153.
96. Norton ME, Merrill J, Cooper BA, Kuller JA, Clyman RI. Neonatal complications after the administration of indomethacin for preterm labor. New England Journal of Medicine 1993;329(22):1602-7.
97. Perron N, Tremblay E, Ferretti E, Babakissa C, Seidman EG, Levy E, et al. Deleterious effects of indomethacin in the mid-gestation human intestine. Genomics 2013;101(3):171-7.
98. Petrou S, Eddama O, Mangham L. A structured review of the recent literature on the economic consequences of preterm birth. Archives of Disease in Childhood. Fetal and Neonatal Edition 2011;96(3):F225-32.
99. Powell SL, Holt VL, Hickok DE, Easterling T, Connell FA. Recent changes in delivery site of low-birth-weight infants in Washington: impact on birth weight-specific mortality. American Journal of Obstetrics and Gynecology 1995;173(5):1585-92.
100. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
101. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2]
102. Sanchez-Ramos L, Kaunitz AM, Gaudier FL, Delke I. Efficacy of maintenance therapy after acute tocolysis: a meta-analysis. American Journal of Obstetrics and Gynecology 1999;181:484-90.
103. Slater DM, Dennes WJB, Campa JS, Poston L, Bennett PR. Expression of cyclo-oxygenase types-1 and -2 in human myometrium throughout pregnancy. Molecular Human Reproduction 1999;5(9):880-4.
104. Souter D, Harding J, McCowan L, O'Donnell C, McLeay E, Baxendale H. Antenatal indomethacin-adverse fetal effects confirmed. Australian and New Zealand Journal of Obstetrics and Gynaecology 1998;38(1):11-6.
105. Su LL, Samuel M, Chong YS. Progestational agents for treating threatened or established preterm labour. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD006770.pub2]
106. Van den Veyver IB, Moise KJ. Prostaglandin synthetase inhibitors in pregnancy. Obstetrical & Gynecological Survey 1993;48(7):493-502.
107. Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Combination of tocolytic agents for inhibiting preterm labour. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD006169.pub2]
108. Walker MW, Clark RH, Spitzer AR. Elevation in plasma creatinine and renal failure in premature neonates without major anomalies: terminology, occurrence and factors associated with increased risk. Journal of Perinatology 2011;31(3):199-205.
109. Howson CP, Kinney MV, Lawn JE. Born Too Soon: The Global Action Report on Preterm Birth. Geneva: World Health Organization, 2012.
110. Yelland LN, Saltera AB, Ryana P, Makrides M. Analysis of binary outcomes from randomised trials including multiple births: when should clustering be taken into account?. Paediatric and Perinatal Epidemiology 2011;25:283-97.
111. King JF, Flenady V, Cole S, Thornton S. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD001992.pub2]